Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.

Trial Details

NCT ID
NCT06627244
Phase
PHASE2
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Tebentafusp
  • TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Metastatic uveal melanoma, confined mainly to the liver, and documented by pathology review
  • Serum bilirubin \<2 mg/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x upper limit of normal (ULN)
  • Mapping angiogram procedure shows radioembolization is feasible and safe to perform
  • Human leukocyte antigen-A\*02:01(HLA A⁕ 02:01) positive

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →